In HCC, anti-angiogenic therapies commonly involve large-molecule monoclonal antibodies targeting VEGF or vascular endothelial growth factor receptor (VEGFR), as well as small molecule tyrosine kinase inhibitors (TKIs) targeting multiple receptors. Here, VEGFA is linked to hepatocellular carcinoma.